See more : Hainan Strait Shipping Co.,Ltd. (002320.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Mesoblast Limited (MESO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mesoblast Limited, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Institution for a Global Society Corporation (4265.T) Income Statement Analysis – Financial Results
- Valid Soluções S.A. (VSSPY) Income Statement Analysis – Financial Results
- Cresud Sociedad Anónima, Comercial, Inmobiliaria, Financiera y Agropecuaria (CRESY) Income Statement Analysis – Financial Results
- Reckitt Benckiser Group plc (RBGLY) Income Statement Analysis – Financial Results
- Pebble Beach Systems Group plc (PEB.L) Income Statement Analysis – Financial Results
Mesoblast Limited (MESO)
About Mesoblast Limited
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.90M | 7.50M | 10.21M | 7.46M | 32.16M | 16.72M | 17.34M | 2.41M | 42.55M | 23.75M | 25.98M | 28.79M | 38.28M | 120.92M | 5.50K | 890.71K | 909.81K | 1.68M | 2.82M | 502.89K |
| Cost of Revenue | 41.07M | 54.92M | 63.57M | 85.73M | 81.50M | 75.17M | 5.51M | 12.07M | 29.76M | 23.78M | 25.43M | 21.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -35.17M | -47.42M | -53.36M | -78.28M | -49.34M | -58.45M | 11.83M | -9.65M | 12.79M | -35.00K | 546.00K | 7.52M | 38.28M | 120.92M | 5.50K | 890.71K | 909.81K | 1.68M | 2.82M | 502.89K |
| Gross Profit Ratio | 100.00% | -632.20% | -522.58% | -1,049.83% | -153.44% | -349.55% | 68.24% | -400.21% | 30.05% | -0.15% | 2.10% | 26.12% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 25.35M | 27.19M | 32.82M | 53.01M | 56.19M | 59.82M | 65.93M | 58.91M | 50.01M | 77.59M | 55.31M | 43.11M | 36.94M | 15.31M | 7.57M | 7.15M | 6.21M | 4.58M | 5.36M | 491.77K |
| General & Administrative | 23.63M | 25.37M | 27.21M | 30.87M | 25.61M | 21.63M | 21.91M | 23.01M | 22.50M | 36.17M | 26.56M | 30.73M | 28.05M | 11.84M | 3.57M | 3.17M | 2.64M | 4.11M | 3.75M | 997.65K |
| Selling & Marketing | 0.00 | 27.73M | 30.76M | 32.72M | 25.31M | 15.36M | 5.51M | 12.07M | 29.76M | 29.21M | 27.61M | 20.95M | 22.02M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 23.63M | 53.11M | 57.97M | 63.59M | 50.92M | 36.98M | 27.42M | 35.07M | 52.26M | 65.38M | 54.17M | 51.68M | 28.05M | 11.84M | 3.57M | 3.17M | 2.64M | 4.11M | 3.75M | 997.65K |
| Other Expenses | 0.00 | 0.00 | 30.76M | 32.65M | 25.23M | 15.48M | -1.31M | 10.53M | 25.92M | 122.00K | 16.49M | 15.02M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 48.98M | 76.79M | 90.79M | 115.06M | 107.56M | 97.88M | 92.03M | 92.50M | 98.44M | 137.14M | 98.36M | 88.86M | 64.99M | 27.16M | 11.13M | 10.32M | 8.85M | 8.69M | 9.11M | 1.49M |
| Cost & Expenses | 90.05M | 76.79M | 90.79M | 115.06M | 107.56M | 97.88M | 92.03M | 92.50M | 98.44M | 137.14M | 98.36M | 88.86M | 64.99M | 27.16M | 11.13M | 10.32M | 8.85M | 8.69M | 9.11M | 1.49M |
| Interest Income | 0.00 | 831.00K | 3.00K | 22.00K | 542.00K | 719.00K | 366.00K | 468.00K | 1.08M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 739.79K | 704.41K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 19.44M | 16.91M | 10.71M | 13.33M | 11.33M | 1.83M | 0.00 | 9.31M | 10.53M | 4.33M | 0.00 | 289.00 | 14.91K | 0.00 | 0.00 | 0.00 | 542.00 | 110.09K | 107.12K |
| Depreciation & Amortization | 1.90M | 4.11M | 4.38M | 4.26M | 3.67M | 2.14M | 2.65M | 3.06M | 2.19M | 1.96M | 1.12M | 772.00K | 378.59K | 178.88K | 153.29K | 119.83K | 156.76K | 62.52K | 43.58K | 18.98K |
| EBITDA | -56.08M | -58.55M | -76.57M | -107.60M | -75.41M | -78.06M | -74.69M | -87.16M | -28.07M | -90.19M | -67.01M | -59.31M | -48.34M | 92.44M | -10.97M | -9.31M | -7.78M | -6.95M | -8.14M | -1.34M |
| EBITDA Ratio | -1,064.44% | -866.94% | -749.91% | -1,443.17% | -234.50% | -485.36% | -430.71% | -3,729.48% | -65.98% | -487.90% | -257.92% | -206.02% | -68.78% | 76.44% | -199,515.44% | -1,045.14% | -855.44% | -515.99% | -288.65% | -267.31% |
| Operating Income | -84.15M | -69.29M | -80.57M | -109.10M | -74.87M | -80.20M | -77.34M | -90.04M | -55.89M | -113.39M | -72.38M | -60.08M | -48.72M | 93.76M | -10.39M | -9.43M | -7.94M | -7.01M | -6.28M | -986.54K |
| Operating Income Ratio | -982.24% | -923.73% | -789.09% | -1,463.20% | -232.84% | -479.62% | -445.99% | -3,733.08% | -131.35% | -477.48% | -278.58% | -208.71% | -127.28% | 77.54% | -188,851.78% | -1,058.60% | -872.67% | -417.64% | -222.70% | -196.18% |
| Total Other Income/Expenses | -4.00M | -12.81M | -10.48M | 9.47M | -12.48M | -18.34M | 9.24M | -173.00K | -34.93M | -4.45M | -3.15M | 0.00 | -289.00 | -1.52M | -4.39M | -2.86M | -2.12M | -1.71M | -2.01M | -483.83K |
| Income Before Tax | -88.15M | -82.10M | -91.59M | -99.63M | -87.36M | -98.75M | -65.98M | -90.22M | -90.82M | -119.37M | -80.95M | -60.08M | -48.72M | 92.24M | -14.78M | -12.29M | -10.06M | -8.73M | -8.30M | -1.47M |
| Income Before Tax Ratio | -1,493.51% | -1,094.53% | -896.93% | -1,336.24% | -271.66% | -590.56% | -380.47% | -3,740.26% | -213.46% | -502.64% | -311.60% | -208.71% | -127.28% | 76.28% | -268,743.55% | -1,379.29% | -1,105.99% | -519.74% | -294.09% | -292.39% |
| Income Tax Expense | 191.00K | -212.00K | -239.00K | -819.00K | -9.42M | -8.96M | -30.69M | -13.40M | -86.69M | 6.10M | 5.00K | 1.59M | 22.42M | 1.63M | -739.79K | 0.00 | 0.00 | -1.71M | -1.79M | -269.59K |
| Net Income | -87.96M | -81.89M | -91.35M | -98.81M | -77.94M | -89.80M | -35.29M | -76.82M | -4.13M | -119.37M | -80.96M | -61.66M | -71.15M | 90.61M | -14.78M | -12.29M | -10.06M | -8.73M | -8.30M | -1.47M |
| Net Income Ratio | -1,490.27% | -1,091.71% | -894.59% | -1,325.25% | -242.38% | -537.01% | -203.51% | -3,184.70% | -9.70% | -502.64% | -311.62% | -214.21% | -185.86% | 74.93% | -268,743.55% | -1,379.29% | -1,105.99% | -519.74% | -294.09% | -292.39% |
| EPS | -0.09 | -0.11 | -0.14 | -0.16 | -0.14 | -0.17 | -0.07 | -0.14 | -0.01 | -0.22 | -0.15 | -0.11 | -0.13 | 0.41 | -0.03 | -0.02 | -0.02 | -0.02 | -0.02 | 0.00 |
| EPS Diluted | -0.09 | -0.11 | -0.14 | -0.16 | -0.14 | -0.17 | -0.07 | -0.14 | -0.01 | -0.22 | -0.15 | -0.11 | -0.13 | 0.39 | -0.03 | -0.02 | -0.02 | -0.02 | -0.02 | 0.00 |
| Weighted Avg Shares Out | 986.70M | 739.04M | 648.78M | 605.07M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M |
| Weighted Avg Shares Out (Dil) | 986.70M | 739.04M | 648.90M | 605.09M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M |
FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease
Earlier this year FDA granted REVASCOR both Rare Pediatric Disease Designation (RPDD) and Orphan-Drug Designation (ODD) for congenital heart disease Earlier this year FDA granted REVASCOR both Rare Pediatric Disease Designation (RPDD) and Orphan-Drug Designation (ODD) for congenital heart disease
Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation
Phase 3 trial results published in European Journal of Heart Failure identify key target population for Mesoblast allogeneic cell therapy Phase 3 trial results published in European Journal of Heart Failure identify key target population for Mesoblast allogeneic cell therapy
Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the first quarter ended September 30, 2024.
Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential
Mesoblast Limited is advancing innovative cellular therapies, with Remestemcel-L for pediatric SR-aGVHD nearing FDA approval and a PDUFA date set for January 2025. Positive Phase 3 results indicate that Remestemcel-L significantly improves response rates and survival in pediatric patients. Additionally,...
Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch
NEW YORK, Sept. 29, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has entered into a convertible note subscription agreement with its largest shareholder Gregory George (“Investor”) for...
Mesoblast Limited (MESO) Q4 2024 Earnings Call Transcript
Mesoblast Limited (NASDAQ:MESO ) Q4 2024 Earnings Conference Call August 28, 2024 6:30 PM ET Company Participants Silviu Itescu - Chief Executive Officer and Managing Director Andrew Chaponnel - Interim Chief Financial Officer Conference Call Participants Edward Tenthoff - Piper...
Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024
NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational update and reported financial results for the period ended June 30, 2024. Mesoblast Chief Executive...
Mesoblast Financial Results and Corporate Update Webcast
NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the full year ended June 30, 2024.
Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024
Ryoncil BLA Submission Under FDA Review for Approval in Children with SR-aGVHD Ryoncil BLA Submission Under FDA Review for Approval in Children with SR-aGVHD
FDA Accepts Mesoblast's Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)
If Approved, RYONCIL will be the First Allogeneic “Off-the-Shelf” Cellular Medicine in the US, and the First Cell Therapy for Children Up To 18 Years Old with SR-aGVHD If Approved, RYONCIL will be the First Allogeneic “Off-the-Shelf” Cellular Medicine in...
Source: https://incomestatements.info
Category: Stock Reports